Brain tumor treatments systemic cyclophosphamide alone or with local adoptive transfer of lymphokine activated killer cells derived from normal or cyclophosphamide treated rats
Eule, J.M.; Parra, J.R.; Lucero, M.D.; Kong, Q.; Mitchell, D.H.; Lillehel, K.O.; Demasters, B.K.; Kruse, C.A.
Clinical Research 40(1): 63A
1992
ISSN/ISBN: 0009-9279 Accession: 030351903
PDF emailed within 1 workday: $29.90
Related References
Nojiri, S.; Kohgo, Y. 1990: Adoptive chemoimmunotherapy for advanced cancer patients with cyclophosphamide interleukin 2 and lymphokine activated killer cells Sapporo Medical Journal 59(5): 505-516Hosokawa, M.; Sawamura, Y.; Morikage, T.; Okada, F.; Xu, Z.Y.; Morikawa, K.; Itoh, K.; Kobayashi, H. 1988: Improved therapeutic effects of interleukin 2 after the accumulation of lymphokine-activated killer cells in tumor tissue of mice previously treated with cyclophosphamide Cancer Immunology Immunotherapy: Cii 26(3): 250-256
Lee, K.; O'Donnell, R.W.; Cockett, A.T. 1988: Ineffectiveness of adoptive chemoimmunotherapy with lymphokine-activated killer cells, interleukin-2, and cyclophosphamide on palpable intradermal murine bladder cancer Journal of Biological Response Modifiers 7(1): 43-53
Yoshimori, K. 1992: A study to increase the therapeutic effects of adoptive immunotherapy in vivo. Influence on the generation of lymphokine activated killer (LAK) cells and therapeutic effects of LAK cells with anti-tumor drug (cyclophosphamide) Nihon Ika Daigaku Zasshi 59(5): 418-427
Tomita, Y.; Katagiri, A.; Saito, K.; Imai, T.; Saito, T.; Tanikawa, T.; Terunuma, M.; Nishiyama, T.; Takahashi, K. 1998: Adoptive immunotherapy of patients with metastatic renal cell cancer using lymphokine-activated killer cells, interleukin-2 and cyclophosphamide: long-term results International Journal of Urology: Official Journal of the Japanese Urological Association 5(1): 16-21
Berdeja, J.ús.G.; Hess, A.; Lucas, D.M.; O'Donnell, P.; Ambinder, R.F.; Diehl, L.F.; Carter-Brookins, D.; Newton, S.; Flinn, I.W. 2007: Systemic interleukin-2 and adoptive transfer of lymphokine-activated killer cells improves antibody-dependent cellular cytotoxicity in patients with relapsed B-cell lymphoma treated with rituximab Clinical Cancer Research: An Official Journal of the American Association for Cancer Research 13(8): 2392-2399
Raman, C.; Gourakanti, N.; Mcconnachie, P.R.; Tewari, R.P. 1990: Adoptive transfer of natural killer nk cells restores resistance to histoplasmosis in cyclophosphamide treated mice FASEB Journal 4(4): A1025
Eggermont, A.M.; Sugarbaker, P.H. 1988: Efficacy of chemoimmunotherapy with cyclophosphamide, interleukin-2 and lymphokine activated killer cells in an intraperitoneal murine tumour model British Journal of Cancer 58(4): 410-414
Eggermont, A.M.; Sugarbaker, P.H. 1989: Efficacy of intracavitary administration of cyclophosphamide, interleukin-2 and lymphokine activated killer cells against established intraperitoneal tumor Acta Medica Austriaca 16(3-4): 47-50
Walewski, J.; Paietta, E.; Dutcher, J.; Wiernik, P.H. 1989: Evaluation of natural killer and lymphokine-activated killer (LAK) cell activity in vivo in patients treated with high-dose interleukin-2 and adoptive transfer of autologous LAK cells Journal of Cancer Research and Clinical Oncology 115(2): 170-174
Kazunori Kato; Toshifumi Tanabe; Toshinori Agatsuma; Shinya Suzuki; Hironobu Nitanai; Yoshiyuki Hashimoto 1991: Augmentation by Tumor Necrosis Factor α of the Systemic Therapeutic Effect of Lymphokine-activated Killer Cells in Adoptive Immunotherapy of Murine Tumor Cancer Science 82(4): 464-469
Kato, K.; Tanabe, T.; Agatsuma, T.; Suzuki, S.; Nitanai, H.; Hashimoto, Y. 1991: Augmentation by tumor necrosis factor alpha of the systemic therapeutic effect of lymphokine-activated killer cells in adoptive immunotherapy of murine tumor Japanese Journal of Cancer Research: Gann 82(4): 464-469
Fabbri, L.; Ridolfi, R.; Riccobon, A.; Maltoni, R.; Flamini, E.; Fedriga, R.; Flamigni, A.; Migliori, G.; Ortolani, F.; Calzolari, F. 1995: Liver metastases from gastric carcinoma: report of a patient treated with adoptive immunotherapy (tumor-infiltrating lymphocytes plus interleukin-2 and subsequently local-regional lymphokine-activated killer cells plus interleukin-2) Tumori 81(6): 445-449
Ballas, Z.K. 1986: Lymphokine-activated killer (LAK) cells. I. Differential recovery of LAK, natural killer cells, and cytotoxic T lymphocytes after a sublethal dose of cyclophosphamide Journal of Immunology 137(7): 2380-2384
Berdeja, J.G.; Hess, A.; Lucas, D.M.; Odonnell, P.; Ambinder, R.F.; Diehl, L.F.; Carterbrookins, D.; Newton, S.; Flinn, L.W. 2007: Systemic lnterleukin-2 and adoptive transfer of lymphokine-activated killer cells improves antibody-dependent cellular cytotoxicity in patients with relapsed b-cell lymphomatreated with rituximab Clinical Cancer Research 13(8): 2392-2399